Abstract
Purpose
The aims of this study are to elucidate if molecular markers can be used to differentiate between the two main types of ameloblastoma (unicystic and solid/multicystic), and to determine whether a biologically ‘less-aggressive’ subtype exists.
Methods
A retrospective analysis of 33 solid/multicystic ameloblastomas and six unicystic ameloblastomas was completed using immunohistochemistry for five molecular markers: P16, P53, MMP-9, Survivin, and Ki-67. Tumors were graded as either negative or positive (mild, moderate, strong), and the results were related to both ameloblastoma subtypes and outcomes following treatment.
Results
Unicystic ameloblastomas were more likely to test strongly positive for P53 than solid/multicystic ameloblastomas (p < 0.05), whereas the latter were more likely to be negative for Survivin (p < 0.05). Solid/multicystic and Type 3 unicystic ameloblastomas that were positive for P16, but also negative for MMP-9 and Survivin, were less likely to recur than all other tumors (p < 0.05). The proliferation index of an ameloblastic carcinoma (11 %) was shown to be higher than benign ameloblastomas (4.5 %).
Conclusions
Immunohistochemistry can be valuable in lesions where histological sub-typing of an ameloblastoma is unclear. A biologically ‘less-aggressive’ subtype may exist, and hence further research into this area is required.
Similar content being viewed by others
References
Kumamoto H (2006) molecular pathology of odontogenic. J Oral Pathol Med 35:65–74
Li T, Wu Y, Yu S, Yu G (2000) Unicystic ameloblastoma: a clinicopathologic study of 33 Chinese patients. Am J Surg Pathol 24(10):1385–1392
Singh TSC (2009) Ameloblastoma: report on two cases and review of the literature. N Z Dent J 105(1):13–17
Gardner D, Heikinheimo K, Shear M, Philipsen H, Coleman H (2005) Ameloblastoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. International Agency for Research on Cancer, Lyon
Artese L, Lessi G, Piattelli A, Rubini C, Goteri G, Pernotti V, Piccirilli M, Carinci F (2008) p16 expression in odontogenic cysts. Dent Res J 5(2):61–64
Artese L, Piattelli A, Rubini C, Goteri G, Pernotti V, Lessi G, Piccirilli M, Carinci F (2008) p16 expression and odontogenic tumours. Tumori 94:718–723
Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, St John MA (2010) Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope 120(9):1788–1794. doi:10.1002/lary.21044
Yamamoto T, Tanigawa N (2001) The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34(4):207–212. doi:10.1007/s007950100017
Kumamoto H, Ooya K (2004) Expression of survivin and X chromosome-linked inhibitor of apoptosis protein in ameloblastomas. Virchows Arch 444(2):164–170. doi:10.1007/s00428-003-0941-9
Kumamoto HIT, Ohki K, Takahashi N, Ooya K (2004) p53 gene status and expression of p53, MDM2, and p14ARF proteins in ameloblastomas. J Oral Pathol Med 33:292–299
Sharifi-Sistani N, Zartab H, Babakoohi S, Saghravanian N, Jamshidi S, Esmaili H, Mohtasham N, Zamanzadeh M, Abbaszadeh-Bidokhty H (2011) Immunohistochemical comparison of the expression of p53 and MDM2 proteins in ameloblastomas and keratocystic odontogenic tumors. J Craniofac Surg 22(5):1652–1656. doi:10.1097/SCS.0b013e31823188e9
Gadbail AR, Chaudhary M, Patil S, Gawande M (2009) Actual Proliferating Index and p53 protein expression as prognostic marker in odontogenic cysts. Oral Dis 15(7):490–498. doi:10.1111/j.1601-0825.2009.01590.x
Gurgel CA, Ramos EA, Azevedo RA, Sarmento VA, da Silva Carvalho AM, dos Santos JN (2008) Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. J Mol Histol 39(3):311–316. doi:10.1007/s10735-008-9167-0
Salehinejad JZ-MR, Saghafi S, Jafarian AH, Ghazi N, Rajaei AR, Marouzi P (2011) Immunohistochemical detection of p53 and pCNA in ameloblastoma and adenomatoid odontogenic tumor. J Oral Sci 53(2):213–217
Chaturvedi AK (2012) Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 6(Suppl 1):S16–S24. doi:10.1007/s12105-012-0377-0
Ang K, Sturgis E (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22(2):128–142
Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, El-Mofty SK (2010) p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 34(8):1088–1096. doi:10.1097/PAS.0b013e3181e84652
Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG (2003) Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 163(2):477–491
Kobayashi S, Shirasawa H, Sashiyama H, Kawahira H, Kaneko K, Asano T, Ochiai T (1999) P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 5(12):4182–4185
Kumamoto H, Kimi K, Ooya K (2001) Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 30:309–315
Zhong Y, Guo W, Wang L, Chen X (2011) Molecular markers of tumor invasiveness in ameloblastoma: an update. Ann Maxillofac Surg 1(2):145. doi:10.4103/2231-0746.92780
Ribeiro BF, Iglesias DP, Nascimento GJ, Galvao HC, Medeiros AM, Freitas RA (2009) Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma and odontogenic adenomatoid tumor. Oral Dis 15(7):472–477. doi:10.1111/j.1601-0825.2009.01575.x
Pinheiro JJVFV, Moretti AIS, Jorge AG, Jaeger RG (2004) Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity. Histopathology 45:65–72
Henriques AC, Vasconcelos MG, Galvao HC, de Souza LB, de Almeida Freitas R (2011) Comparative analysis of the immunohistochemical expression of collagen IV, MMP-9, and TIMP-2 in odontogenic cysts and tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(4):468–475. doi:10.1016/j.tripleo.2011.05.033
Rosenthal EL, Matrisian LM (2006) Matrix metalloproteases in head and neck cancer. Head Neck 28(7):639–648. doi:10.1002/hed.20365
Kumamoto H, Yamauchi K, Yoshida M, Ooya K (2003) Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 32:114–120
Yoon HJ, Jo BC, Shin WJ, Cho YA, Lee JI, Hong SP, Hong SD (2011) Comparative immunohistochemical study of ameloblastoma and ameloblastic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(6):767–776. doi:10.1016/j.tripleo.2011.06.036
Zhang B, Zhang J, Huang HZ, Chen WL, Tao Q, Zeng DL, Zhang LT, Xu JH (2009) Inhibition of ameloblastoma invasion in vitro and in vivo by inhibitor of metalloproteinase-2 activity. J Oral Pathol Med 38(9):731–736. doi:10.1111/j.1600-0714.2009.00771.x
Wang A, Zhang B, Huang H, Zhang L, Zeng D, Tao Q, Wang J, Pan C (2008) Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC Cancer 8:182. doi:10.1186/1471-2407-8-182
Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, de Almeida OP, Carrasco-Daza D, Farfan-Morales JE, Molina-Frechero N, Damian-Matsumura P (2009) Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma. Pathol Int 59(4):229–233. doi:10.1111/j.1440-1827.2009.02355.x
Slootweg PJ (1995) p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 24(9):393–397
Jaaskelainen KJK, Leivo I, Saloniemi I, Knuutila S, Heikinheimo K (2002) Cell proliferation and chromosomal changes in human ameloblastoma. Cancer Genet Cytogenet 136:31–37
Akrish S, Buchner A, Shoshani Y, Vered M, Dayan D (2007) Ameloblastic carcinoma: report of a new case, literature review, and comparison to ameloblastoma. J Oral Maxillofac Surg 65(4):777–783. doi:10.1016/j.joms.2005.11.116
Bello IO, Alanen K, Slootweg PJ, Salo T (2009) Alpha-smooth muscle actin within epithelial islands is predictive of ameloblastic carcinoma. Oral Oncol 45(9):760–765. doi:10.1016/j.oraloncology.2008.11.011
Sandra F, Mitsuyasu T, Nakamura N, Shiratsuchi Y, Ohishi M (2001) Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol 37(2):193–198
Florescu A, Simionescu C, Ciurea R, Pitru A (2012) P53, Bcl-2 and Ki67 immunoexpression in follicular solid ameloblastomas. Rom J Morphol Embryol 53(1):105–109
Razavi S, Tabatabaie S, Hoseini A, Hoseini E, Khabazia A (2012) A comparative immunohistochemical study of Ki-67 and Bcl-2 expression in solid ameloblastoma and adenomatoid odontogenic tumor. Dent Res J 9(2):192–197
Soluk Tekkesin M, Mutlu S, Olgac V (2012) Expressions of bax, bcl-2 and Ki-67 in odontogenic keratocysts (keratocystic odontogenic tumor) in comparison with ameloblastomas and radicular cysts. Turk Patoloji Derg 28(1):49–55. doi:10.5146/tjpath.2012.01097
Acknowledgments
The authors would like to acknowledge the staff at the Anatomical and Pathology Laboratory at The Royal Melbourne Hospital. Special thanks to Associate Professor Nastri and Associate Professor Wiesenfeld for their assistance in this study. A research grant was kindly provided by the Australia and New Zealand Association of Oral and Maxillofacial Surgeons (ANZAOMS) Research and Education Foundation Inc. and Trust.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, T., Chandu, A., Clement, J. et al. Immunohistochemistry of Five Molecular Markers for Typing and Management of Ameloblastomas: A Retrospective Analysis of 40 Cases. J. Maxillofac. Oral Surg. 16, 65–70 (2017). https://doi.org/10.1007/s12663-016-0923-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12663-016-0923-5